Identification of Dysregulated Expression of G Protein Coupled Receptors in Endocrine Tumors by Bioinformatics Analysis: Potential Drug Targets?
G protein-coupled receptors
adrenocortical cancer
drug repurposing
endocrine tumors
medullary thyroid cancer
paraganglioma
pheochromocytoma
pituitary adenoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
17 02 2022
17 02 2022
Historique:
received:
14
01
2022
revised:
15
02
2022
accepted:
15
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Many studies link G protein-coupled receptors (GPCRs) to cancer. Some endocrine tumors are unresponsive to standard treatment and/or require long-term and poorly tolerated treatment. This study explored, by bioinformatics analysis, the tumoral profiling of the GPCR transcriptome to identify potential targets in these tumors aiming at drug repurposing. We explored the GPCR differentially expressed genes (DEGs) from public datasets (Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA)). The GEO datasets were available for two medullary thyroid cancers (MTCs), eighty-seven pheochromocytomas (PHEOs), sixty-one paragangliomas (PGLs), forty-seven pituitary adenomas and one-hundred-fifty adrenocortical cancers (ACCs). The TCGA dataset covered 92 ACCs. We identified GPCRs targeted by approved drugs from pharmacological databases (ChEMBL and DrugBank). The profiling of dysregulated GPCRs was tumor specific. In MTC, we found 14 GPCR DEGs, including an upregulation of the dopamine receptor ( We highlight specific GPCR signatures across the major endocrine tumors. These data could help to identify new opportunities for drug repurposing.
Sections du résumé
BACKGROUND
Many studies link G protein-coupled receptors (GPCRs) to cancer. Some endocrine tumors are unresponsive to standard treatment and/or require long-term and poorly tolerated treatment. This study explored, by bioinformatics analysis, the tumoral profiling of the GPCR transcriptome to identify potential targets in these tumors aiming at drug repurposing.
METHODS
We explored the GPCR differentially expressed genes (DEGs) from public datasets (Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA)). The GEO datasets were available for two medullary thyroid cancers (MTCs), eighty-seven pheochromocytomas (PHEOs), sixty-one paragangliomas (PGLs), forty-seven pituitary adenomas and one-hundred-fifty adrenocortical cancers (ACCs). The TCGA dataset covered 92 ACCs. We identified GPCRs targeted by approved drugs from pharmacological databases (ChEMBL and DrugBank).
RESULTS
The profiling of dysregulated GPCRs was tumor specific. In MTC, we found 14 GPCR DEGs, including an upregulation of the dopamine receptor (
CONCLUSIONS
We highlight specific GPCR signatures across the major endocrine tumors. These data could help to identify new opportunities for drug repurposing.
Identifiants
pubmed: 35203352
pii: cells11040703
doi: 10.3390/cells11040703
pmc: PMC8870215
pii:
doi:
Substances chimiques
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Plan National Cancer-Inserm
ID : Plan National Cancer-Inserm
Organisme : Pfizer (France)
ID : Endocrinology Reserach Price
Références
Invest New Drugs. 2020 Apr;38(2):311-320
pubmed: 31087223
J Steroid Biochem Mol Biol. 2019 Oct;193:105434
pubmed: 31351131
Nat Rev Cancer. 2013 Jun;13(6):412-24
pubmed: 23640210
Mol Pharmacol. 2018 Apr;93(4):251-258
pubmed: 29298813
Nat Rev Cancer. 2007 Feb;7(2):79-94
pubmed: 17251915
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93
pubmed: 16609007
Endocr Pathol. 2016 Jun;27(2):104-14
pubmed: 26860936
J Surg Res. 2010 Apr;159(2):696-704
pubmed: 19515383
Nat Rev Drug Discov. 2017 Dec;16(12):829-842
pubmed: 29075003
PLoS Biol. 2019 Nov 25;17(11):e3000434
pubmed: 31765370
Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2275-85
pubmed: 18768493
FASEB J. 2018 Mar;32(3):1170-1183
pubmed: 29092903
Pharmaceutics. 2019 Sep 02;11(9):
pubmed: 31480803
Cells. 2021 Dec 16;10(12):
pubmed: 34944065
Front Pharmacol. 2018 May 22;9:431
pubmed: 29872392
Nat Rev Drug Discov. 2011 Jan;10(1):47-60
pubmed: 21193867
J Clin Endocrinol Metab. 2021 Jul 13;106(8):2221-2232
pubmed: 34000025
BMC Bioinformatics. 2015 May 22;16:169
pubmed: 25994840
Surgery. 2013 Dec;154(6):1405-16; discussion 1416
pubmed: 24238056
Folia Histochem Cytobiol. 2008;46(1):51-5
pubmed: 18296263
Endocrinology. 2008 Mar;149(3):1235-42
pubmed: 18079202
Acta Neuropathol Commun. 2019 Nov 8;7(1):172
pubmed: 31703742
PLoS One. 2014 Apr 03;9(4):e90458
pubmed: 24699253
PLoS One. 2016 Mar 10;11(3):e0150629
pubmed: 26963385
Cell Signal. 2015 Dec;27(12):2579-88
pubmed: 26321231
Neoplasia. 2013 Apr;15(4):435-47
pubmed: 23555188
J Histochem Cytochem. 2014 Mar 26;62(6):395-404
pubmed: 24670796
Am J Physiol Endocrinol Metab. 2001 Feb;280(2):E209-13
pubmed: 11158922
Acta Neuropathol Commun. 2015 May 21;3:30
pubmed: 25990246
Oncotarget. 2016 Mar 22;7(12):14605-15
pubmed: 26910279
Endocrinology. 2012 Aug;153(8):3679-91
pubmed: 22635680
Genomics. 2006 Sep;88(3):263-73
pubmed: 16753280
J Pathol. 1999 May;188(1):87-92
pubmed: 10398146
Oncogene. 2019 Jul;38(27):5381-5395
pubmed: 30867568
J Mol Med (Berl). 2015 Jan;93(1):93-104
pubmed: 25263965
Sci Rep. 2015 Jun 08;5:10775
pubmed: 26053859
J Biol Chem. 2019 Jul 19;294(29):11062-11086
pubmed: 31171722
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Biomed Res Int. 2018 Oct 17;2018:1823726
pubmed: 30417009
J Pathol. 2013 May;230(1):70-81
pubmed: 23338946
Lab Invest. 2002 Oct;82(10):1305-17
pubmed: 12379765
J Pathol. 2008 May;215(1):87-96
pubmed: 18306168
Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954
pubmed: 27899562
Int J Oncol. 2018 Jun;52(6):1934-1946
pubmed: 29620167
Endocr Relat Cancer. 2009 Jun;16(2):573-83
pubmed: 19218281
Endocr Relat Cancer. 2017 Apr;24(4):C5-C8
pubmed: 28264912
Curr Med Chem. 2020;27(41):7112-7132
pubmed: 32586246
Oncogene. 2005 Oct 6;24(44):6646-56
pubmed: 16007166
Oncotarget. 2018 May 18;9(38):24882-24897
pubmed: 29861840
Oncogene. 2015 May 28;34(22):2922-33
pubmed: 25043296
Oncotarget. 2018 Jan 11;9(10):9177-9198
pubmed: 29507682
Eur J Endocrinol. 2018 Jan;178(1):G1-G24
pubmed: 29046323
Thyroid. 2006 Dec;16(12):1229-42
pubmed: 17199433
Horm Metab Res. 1995 Sep;27(9):408-14
pubmed: 8557239
Nature. 2009 May 21;459(7245):356-63
pubmed: 19458711
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Swiss Med Wkly. 2015 Sep 16;145:w14183
pubmed: 26375999
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807
Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6
pubmed: 18048412
Mol Endocrinol. 2009 Oct;23(10):1681-90
pubmed: 19574446
Mol Endocrinol. 2010 Dec;24(12):2382-91
pubmed: 20980436
Pituitary. 2015 Jun;18(3):335-42
pubmed: 24917361
Endocr Relat Cancer. 2009 Sep;16(3):895-906
pubmed: 19546168
Neuroendocrinology. 2021;111(10):937-950
pubmed: 33075795
Sci Transl Med. 2019 Jun 26;11(498):
pubmed: 31243151
Am J Pathol. 2012 Sep;181(3):1017-33
pubmed: 22800756